View Filing Data

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2020	Mar. 31, 2019
Disaggregation Of Revenue [Line Items]
Net revenues	$ 31,596	$ 30,122
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	21,616	20,566
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,805	2,431
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 7,175	$ 7,125

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 83,365	$ 75,715
Short-term investments	82,735	80,623
Accounts receivable, net of allowance for doubtful accounts of $2,511 and $2,666	27,861	36,948
Inventories	22,694	23,155
Prepaid expenses	2,912	2,433
Other current assets	3,878	5,676
Total current assets	223,445	224,550
Noncurrent Assets:
Property, plant and equipment, net	31,829	30,339
Operating right-of-use assets, net	4,665	4,996
Finance right-of-use assets, net	1,818	1,951
Intangible assets, net	15,746	14,674
Goodwill	34,544	36,201
Long-term investments	10,070	33,420
Other noncurrent assets	2,955	3,164
Total noncurrent assets	101,627	124,745
TOTAL ASSETS	325,072	349,295
Current Liabilities:
Accounts payable	6,881	9,567
Deferred revenue	4,312	3,713
Accrued expenses and other current liabilities	12,339	14,288
Finance lease liability	588	613
Operating lease liability	999	1,032
Acquisition-related contingent consideration obligation	1,220	3,500
Total current liabilities	26,339	32,713
Noncurrent Liabilities:
Finance lease liability	1,281	1,372
Operating lease liability	3,899	4,206
Other noncurrent liabilities	2,641	2,960
Deferred income taxes	760	899
Total noncurrent liabilities	8,581	9,437
TOTAL LIABILITIES	34,920	42,150
Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 62,026 and 61,731 shares issued and outstanding	0	0
Additional paid-in capital	401,812	401,814
Accumulated other comprehensive loss	(21,799)	(12,136)
Accumulated deficit	(89,861)	(82,533)
Total stockholders' equity	290,152	307,145
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 325,072	$ 349,295

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, CoreBiome, Novosanis and Diversigen. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, contingent consideration, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of March 31, 2020, we determined that the decline in the market value of our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary.

The following is a summary of our available-for-sale securities as of March 31, 2020 and December 31, 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
March 31, 2020
Guaranteed investment certificates	$	22,757	$	—	$	—		$	22,757
Corporate bonds		70,604		94		(650	)		70,048
Total available-for-sale securities	$	93,361	$	94	$	(650	)	$	92,805
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At March 31, 2020, maturities of our available-for-sale securities were as follows:
Less than one year	$	83,274	$	94	$	(633	)	$	82,735
Greater than one year	$	10,087	$	—	$	(17	)	$	10,070

Fair Value of Financial Instruments. As of March 31, 2020 and December 31, 2019, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 2 instruments as of March 31, 2020 and December 31, 2019.

Included in cash and cash equivalents at March 31, 2020 and December 31, 2019, was $21,660 and $1,624 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of March 31, 2020 and December 31, 2019 was $3,444 and $3,519, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	March 31, 2020		December 31, 2019
Raw materials	$	13,927	$	14,168
Work in process		865		643
Finished goods		7,902		8,344
	$	22,694	$	23,155

Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of March 31, 2020 and December 31, 2019 was $49,417 and $46,882, respectively.

Intangible Assets. Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of March 31, 2020 and December 31, 2019 was $22,812 and $23,420, respectively. The change in intangibles from $14,674 as of December 31, 2019 to $15,746 as of March 31, 2020 is a result of the acquisition of patent and product rights of $2,250 offset by foreign currency translation losses of $446 and $732 in amortization expense.

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisitions of DNAG, CoreBiome, Novosanis and Diversigen. All acquired goodwill has been allocated to our DNAG segment. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The decrease in goodwill from $36,201 as of December 31, 2019 to $34,544 as of March 31, 2020 is a result of a purchase price adjustment related to one of our acquisitions of $126 and a decrease of $1,531 associated with foreign currency translation.

Leases. In February 2019, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and did not restate comparative amounts. Also, we elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classification, our assessment on whether a contract is or contains a lease, and our initial direct costs for any leases that exist prior to adoption of the new standard. Leases with an initial term of 12 months or less are not recognized on the balance sheet and the associated lease payments are included in the consolidated statements of operations on a straight-line basis over the lease term. As a result, on January 1, 2019, we recorded right-of-use assets of $4,027 and lease liabilities of $4,263 on our consolidated balance sheet.

Business Combinations and Contingent Consideration. Acquired businesses are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to contingent consideration are recorded to the balance sheet at the date of acquisition based on their relative fair values. The purchase price allocation requires us to make significant estimates and assumptions, especially at the acquisition date, with respect to intangible assets. Although we believe the assumptions and estimates we have made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired companies and are inherently uncertain.

We account for contingent consideration in accordance with applicable guidance provided within the business combination accounting standard. As part of our consideration for the CoreBiome and Novosanis acquisitions, we are contractually obligated to pay certain consideration resulting from the outcome of future events. Therefore, we are required to update our underlying assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in our consolidated statements of operations. Our estimates

of fair value are based on assumptions we believe to be reasonable, but the assumptions are uncertain and involve significant judgment by management. Updates to these assumptions could have a significant impact on our results of operations in any given period and any updates to the fair value of the contingent consideration could differ materially from the previous estimates.

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:


	•		future expected cash flows from sales and acquired developed technologies;


	•		the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;


	•		the probability of meeting the future events; and


	•		discount rates used to determine the present value of estimated future cash flows.

Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options, unvested performance stock units, and unvested restricted stock. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.

For the three months ended March 31, 2020 and 2019, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 312 and 779 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in our consolidated statements of income were $693 and $(609) for the three months ended March 31, 2020 and 2019, respectively.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at March 31, 2020 consists of $21,243 of currency translation adjustments and $556 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2019 consists of $12,022 of currency translation adjustments and $114 of net unrealized losses on marketable securities.

Recent Accounting Pronouncements. In June 2016, the FASB issued guidance on the measurement of credit losses, which requires measurement and recognition of expected credit losses for financial assets, including trade receivables and capital lease receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements as credit losses are not expected to be significant based on historical collection trends, the financial condition of payment partners, and external market factors. The Company will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses. In addition, the new guidance requires us to record an allowance for credit loss when a decline in investment market value is due to credit-related factors. As of January 1, 2020, there was no material decline in the market value of available-for-sale investments due to credit-related factors.

In February 2018, the FASB issued guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the U.S. Tax Cuts and Jobs Act. The guidance is effective in fiscal year 2020, with early adoption permitted, including adoption in an interim period. If elected, the reclassification can be applied in either the period of adoption or retrospectively to the period of the enactment of the U.S. Tax Cuts and Jobs Act (i.e., our first quarter of fiscal year 2018). We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.

In August 2018, the FASB issued guidance related to fair value measurement disclosures. This guidance removes the requirement to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy, the policy for determining that a transfer has occurred, and valuation processes for Level 3 fair value measurements. Additionally, this guidance modifies the disclosures related to the measurement uncertainty for recurring Level 3 fair value measurements (by removing the requirement to disclose sensitivity to future changes) and the timing of liquidation of investee assets (by removing the timing requirement in certain instances). The guidance also requires new disclosures for Level 3 financial assets and liabilities, including the amount and location of unrealized gains and losses recognized in other comprehensive income(loss) and additional information related to significant unobservable inputs used in determining Level 3 fair value measurements. This guidance is effective beginning in fiscal year 2020. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Beginning Balance	$ 307,145	$ 283,378
Common stock issued upon exercise of options	$ 30	22
Common stock issued upon exercise of options, Shares	6
Purchase and retirement of common shares	$ (1,408)	(3,595)
Stock-based compensation	1,376	1,231
Net loss	(7,328)	(3,258)
Currency translation adjustments	(9,221)	2,232
Unrealized gain (loss) on marketable securities	(442)	497
Ending Balance	$ 290,152	$ 280,507
Common Stock [Member]
Beginning Balance, Shares	61,731	61,276
Common stock issued upon exercise of options, Shares	6	4
Vesting of restricted stock and performance stock units, Shares	486	664
Purchase and retirement of common shares, Shares	(197)	(277)
Ending Balance, Shares	62,026	61,667
Additional Paid-in Capital [Member]
Beginning Balance	$ 401,814	$ 401,273
Common stock issued upon exercise of options	30	22
Purchase and retirement of common shares	(1,408)	(3,595)
Stock-based compensation	1,376	1,231
Ending Balance	401,812	398,931
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(12,136)	(18,706)
Currency translation adjustments	(9,221)	2,232
Unrealized gain (loss) on marketable securities	(442)	497
Ending Balance	(21,799)	(15,977)
Accumulated Deficit [Member]
Beginning Balance	(82,533)	(99,189)
Net loss	(7,328)	(3,258)
Ending Balance	$ (89,861)	$ (102,447)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2020

Summary of Reconciliation of Changes in Stockholders' Equity

Reconciliation of the changes in stockholders' equity for the three months ended March 31, 2020 and 2019
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2019		61,731		$	—	$	401,814		$	(12,136	)	$	(82,533	)	$	307,145
Common stock issued upon exercise of options		6			—		30			—			—			30
Vesting of restricted stock and performance stock units		486			—		—			—			—			—
Purchase and retirement of common shares		(197	)		—		(1,408	)		—			—			(1,408	)
Stock-based compensation		—			—		1,376			—			—			1,376
Net loss		—			—		—			—			(7,328	)		(7,328	)
Currency translation adjustments										(9,221	)					(9,221	)
Unrealized loss on marketable securities		—			—		—			(442	)		—			(442	)
Balance at March 31, 2020		62,026		$	—	$	401,812		$	(21,799	)	$	(89,861	)	$	290,152


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Stock-based compensation		—			—		1,231			—			—			1,231
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments										2,232						2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2020:

	Options
Outstanding on January 1, 2020		1,193
Granted		510
Exercised		(6	)
Forfeited		(14	)
Outstanding on March 31, 2020		1,683

Summary of Time-Vested Restricted Stock Award and Restricted Stock Units Activity

The following table summarizes time-vested restricted stock award and restricted stock unit activity for the three months ended March 31, 2020:

	Units
Issued and unvested, January 1, 2020		464
Granted		480
Vested		(178	)
Forfeited		(10	)
Issued and unvested, March 31, 2020		756

Performance Based Restricted Stock Unit [Member]

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes the PSU activity for the three months ended March 31, 2020:

	Units
Issued and unvested, January 1, 2020		525
Granted		353
Performance adjustment		103
Vested		(311	)
Forfeited		(35	)
Issued and unvested, March 31, 2020		635

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of March 31, 2020 and December 31, 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
March 31, 2020
Guaranteed investment certificates	$	22,757	$	—	$	—		$	22,757
Corporate bonds		70,604		94		(650	)		70,048
Total available-for-sale securities	$	93,361	$	94	$	(650	)	$	92,805
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At March 31, 2020, maturities of our available-for-sale securities were as follows:
Less than one year	$	83,274	$	94	$	(633	)	$	82,735
Greater than one year	$	10,087	$	—	$	(17	)	$	10,070

Schedule of Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	March 31, 2020		December 31, 2019
Raw materials	$	13,927	$	14,168
Work in process		865		643
Finished goods		7,902		8,344
	$	22,694	$	23,155

Stockholders' Equity

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Stockholders' Equity

7.	Stockholders’ Equity

Reconciliation of the changes in stockholders' equity for the three months ended March 31, 2020 and 2019
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2019		61,731		$	—	$	401,814		$	(12,136	)	$	(82,533	)	$	307,145
Common stock issued upon exercise of options		6			—		30			—			—			30
Vesting of restricted stock and performance stock units		486			—		—			—			—			—
Purchase and retirement of common shares		(197	)		—		(1,408	)		—			—			(1,408	)
Stock-based compensation		—			—		1,376			—			—			1,376
Net loss		—			—		—			—			(7,328	)		(7,328	)
Currency translation adjustments										(9,221	)					(9,221	)
Unrealized loss on marketable securities		—			—		—			(442	)		—			(442	)
Balance at March 31, 2020		62,026		$	—	$	401,812		$	(21,799	)	$	(89,861	)	$	290,152


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Stock-based compensation		—			—		1,231			—			—			1,231
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments										2,232						2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.

Total compensation cost related to stock options for the three months ended March 31, 2020 and 2019 was $253 and $324 respectively. Net cash proceeds from the exercise of stock options were $30 and $22 for the three months ended March 31, 2020 and 2019, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

The following table summarizes the stock option activity for the three months ended March 31, 2020:

	Options
Outstanding on January 1, 2020		1,193
Granted		510
Exercised		(6	)
Forfeited		(14	)
Outstanding on March 31, 2020		1,683

Compensation cost of $1,079 and $653 related to restricted shares was recognized during the three months ended March 31, 2020 and 2019, respectively. In connection with the vesting of restricted shares during the three months ended March 31, 2020 and 2019, we purchased and immediately retired 197 and 277 shares with aggregate values of $1,408 and $3,595, respectively, in satisfaction of minimum tax withholding obligations.

The following table summarizes time-vested restricted stock award and restricted stock unit activity for the three months ended March 31, 2020:

	Units
Issued and unvested, January 1, 2020		464
Granted		480
Vested		(178	)
Forfeited		(10	)
Issued and unvested, March 31, 2020		756

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Performance during the one-year period is based on a one-year earnings per share or income before income taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.

Compensation cost of $44 and $254 related to PSUs was recognized during the three months ended March 31, 2020 and 2019, respectively.

The following table summarizes the PSU activity for the three months ended March 31, 2020:

	Units
Issued and unvested, January 1, 2020		525
Granted		353
Performance adjustment		103
Vested		(311	)
Forfeited		(35	)
Issued and unvested, March 31, 2020		635

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the three months ended March 31, 2020 and 2019.

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-16537
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Common Stock, Shares Outstanding		62,066,000
Document Quarterly Report	true
Document Transition Report	false

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Investments

The following is a summary of our available-for-sale securities as of March 31, 2020 and December 31, 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
March 31, 2020
Guaranteed investment certificates	$	22,757	$	—	$	—		$	22,757
Corporate bonds		70,604		94		(650	)		70,048
Total available-for-sale securities	$	93,361	$	94	$	(650	)	$	92,805
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At March 31, 2020, maturities of our available-for-sale securities were as follows:
Less than one year	$	83,274	$	94	$	(633	)	$	82,735
Greater than one year	$	10,087	$	—	$	(17	)	$	10,070

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 2 instruments as of March 31, 2020 and December 31, 2019.

Accounts Receivable

Inventories

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	March 31, 2020		December 31, 2019
Raw materials	$	13,927	$	14,168
Work in process		865		643
Finished goods		7,902		8,344
	$	22,694	$	23,155

Property, Plant and Equipment

Intangible Assets

Goodwill

Leases

Business Combinations and Contingent Consideration

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:


	•		future expected cash flows from sales and acquired developed technologies;


	•		the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;


	•		the probability of meeting the future events; and


	•		discount rates used to determine the present value of estimated future cash flows.

Loss Per Share

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss)

Recent Accounting Pronouncements

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended March 31,
	2020		2019
OraQuick®	$	13,756	$	11,590
Oragene®		9,633		4,173
ORAcollect®		449		3,225
Intercept®		1,978		1,842
Microbiome laboratory services		2,447		958
OMNIgene® • GUT		693		979
Histofreezer®⁽¹⁾		-		2,213
Other products		1,930		3,352
Net product and services revenues		30,886		28,332

Royalty income		446		1,084
Other non product revenues		264		706
Other revenues		710		1,790
Net revenues	$	31,596	$	30,122

⁽¹⁾

^{On August 16, 2019, we sold all rights and title to the assets necessary to operate our cryosurgical line of business and as such results of operations after August 16, 2019, do not include any revenues associated with that line of business.}

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended March 31,
	2020		2019
United States	$	21,616	$	20,566
Europe		2,805		2,431
Other regions		7,175		7,125
	$	31,596	$	30,122

Customer and Vendor Concentrations

Customer and Vendor Concentrations. One of our customers accounted for 12% of our accounts receivable as of March 31, 2020. Another customer accounted for 19% of our accounts receivable as of December 31, 2019. We had no significant customer concentrations (greater than 10%) in our net consolidated revenues for the three months ended March 31, 2020 and 2019

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its product. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2020 and December 31, 2019 includes customer prepayments of $2,508 and $1,904, respectively. Deferred revenue as of March 31, 2020 and December 31, 2019 also includes $ 1,804 and $1,809, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that rate.

Business Segment Information

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Business Segment Information

10.	Business Segment Information

Our business consists of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our DNAG business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of CoreBiome, Novosanis and Diversigen are included in our DNAG segment. Our cryosurgical systems business was included in our OSUR segment and the impact of the sale of that business in August 2019 is reflected in the results presented below.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three months ended March 31, 2020 and 2019, and asset information as of March 31, 2020 and December 31, 2019:

	Three Months Ended March 31,
	2020			2019
Net revenues:
OSUR	$	17,792		$	18,233
DNAG		13,804			11,889
Total	$	31,596		$	30,122
Operating loss:
OSUR	$	(7,641	)	$	(3,499	)
DNAG		(405	)		(312	)
Total	$	(8,046	)	$	(3,811	)
Depreciation and amortization:
OSUR	$	861		$	822
DNAG		1,336			904
Total	$	2,197		$	1,726
Capital expenditures:
OSUR	$	818		$	1,929
DNAG		1,777			699
Total	$	2,595		$	2,628

	March 31, 2020		December 31, 2019
Total assets:
OSUR	$	174,197	$	163,943
DNAG		150,875		185,352
Total	$	325,072	$	349,295

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:

	Three Months Ended March 31,
	2020		2019
Operating Lease Cost	$	313	$	231
Finance Lease Cost
Amortization of right-of use assets		163		39
Interest on lease liabilities		20		4
Total Finance Lease Cost	$	183	$	43

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Three Months Ended March 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	316	$	228
Operating cash flows from financing leases		20		3
Financing cash flows from financing leases		175		35
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		—		240
Right-of-use assets obtained in exchange for finance lease obligations		—		1,249

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:

	March 31, 2020		December 31, 2019
Operating Leases
Right-of-use assets	$	4,665	$	4,996

Current lease liabilities		999		1,032
Non-current lease liabilities		3,899		4,206
Total operating lease liabilities	$	4,898	$	5,238


Finance Leases
Right-of-use assets	$	1,818	$	1,951

Current lease liabilities		588		613
Non-current lease liabilities		1,281		1,372
Total finance lease liabilities	$	1,869	$	1,985

Summary of Lease Term and Discount Rate

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.05
Weighted-average remaining lease term—finance leases	3.27

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.29	%
Weighted-average discount rate—finance leases	4.32	%

Schedule of Minimum Lease Payments by Period Expected

As of March 31, 2020, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2020 (excluding the three months ended March 31, 2020)	$	512		$	928
2021		565			1,180
2022		565			1,161
2023		336			758
2024		24			776
Thereafter		4			760
Total Minimum Lease Payments		2,006			5,563
Less: imputed interest		(137	)		(665	)
Present Value of Lease Liabilities	$	1,869		$	4,898

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
NET REVENUES:
Total revenue	$ 31,596	$ 30,122
COST OF PRODUCTS AND SERVICES SOLD	15,465	12,042
Gross profit	16,131	18,080
OPERATING EXPENSES:
Research and development	5,644	4,371
Sales and marketing	7,369	7,295
General and administrative	10,054	8,930
Change in the estimated fair value of acquisition-related contingent consideration	1,110	1,295
Total operating expenses	24,177	21,891
Operating loss	(8,046)	(3,811)
OTHER INCOME	1,430	524
Loss before income taxes	(6,616)	(3,287)
INCOME TAX (BENEFIT) EXPENSE	712	(29)
NET LOSS	$ (7,328)	$ (3,258)
LOSS PER SHARE:
BASIC	$ (0.12)	$ (0.05)
DILUTED	$ (0.12)	$ (0.05)
SHARES USED IN COMPUTING LOSS PER SHARE:
BASIC	61,927	61,531
DILUTED	61,927	61,531
Products and Services [Member]
NET REVENUES:
Total revenue	$ 30,886	$ 28,332
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 710	$ 1,790

Business Combinations (Tables)

3 Months Ended

Mar. 31, 2020

Summary of Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the CoreBiome, Diversigen and Novosanis acquisitions as if they had been consummated as of January 1, 2019. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2019.

	Three Months ended
	March 31, 2019

Revenue	$	31,048
Net loss		(3,290	)
Net loss per share, basic and diluted		(0.05	)

Corebiome Inc. and Novosanis NV [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

Diversigen, Inc. [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,317
Total assets acquired		13,072
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Cash Paid (net of cash acquired of $479)	$	10,458

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Customer relationships	10		2,900
Tradenames	9		660
Total acquired intangibles		$	3,560

Business Combinations

3 Months Ended

Mar. 31, 2020

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

CoreBiome and Novosanis

On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement, dated January 3, 2019. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement, dated January 3, 2019. We began operating these entities as of the January 4, 2019 closing date. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above.

During the three months ended March 31, 2019, we incurred a total of $597 of acquisition-related costs in connection with these acquisitions, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the three months ended March 31, 2019.

Pursuant to our acquisition agreements, we were to pay up to an additional $32,400 of contingent consideration over the next three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculated the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration obligation changed from $4,350 as of the acquisition date to $5,625 as of March 31, 2019 as a result of changes in our estimated revenue forecasts. The fair value of the contingent consideration obligation changed from $3,612 as of December 31, 2019 to $1,220 as of March 31, 2020. This change is a result of a $3,500 payment made in the first quarter of 2020, changes in our estimated revenue forecasts and an amendment to one of the agreements. The amendment was entered into in March 2020, in which the terms of the contingent consideration provisions associated with one of the acquisitions were modified and are expected to be paid during the first quarter of 2021. As of March 31, 2020, we may pay up to an additional $22,500 of contingent consideration over the next year and a half.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of CoreBiome and Novosanis. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our DNAG segment.

Revenues from CoreBiome primarily consist of microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment.

Diversigen

On November 8, 2019, the Company acquired all of the outstanding stock of Diversigen pursuant to the terms of a merger agreement. We began operating this entity as of the November 8, 2019 closing date.

The aggregate purchase price for this transaction was $12,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement noted above.

During the three months ended March 31, 2020 and 2019, we did not incur any acquisition related costs associated with this transaction, including investment banking fees and accounting, legal and other professional fees.

Pursuant to our acquisition agreements, we were to pay up to an additional $1,500 of contingent consideration in 2020 based on the achievement of certain 2019 revenue metrics as defined under the agreements which did not occur.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,317
Total assets acquired		13,072
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Cash Paid (net of cash acquired of $479)	$	10,458

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Customer relationships	10		2,900
Tradenames	9		660
Total acquired intangibles		$	3,560

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of Diversigen. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

We continue to evaluate the fair value of certain assets acquired and liabilities assumed. Additional information, which existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from Diversigen primarily consist of microbiome laboratory services that provide metagenomics sequencing, bioinformatics and statistical analysis for the study of the microbiome. Effective as of November 8, 2019, the financial results of Diversigen are included in our DNAG segment.

Unaudited Pro Forma Financial Information

	Three Months ended
	March 31, 2019

Revenue	$	31,048
Net loss		(3,290	)
Net loss per share, basic and diluted		(0.05	)

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Nov. 08, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 83,365		$ 75,715
Fair value of plan assets	3,444		3,519
Accumulated depreciation of property and equipment	49,417		46,882
Accumulated amortization of intangible assets	22,812		23,420
Intangible Assets, Net	15,746		14,674
Intangible Assets, Accumulated Amortization	732
Intangible Assets, Foreign currency translation loss	446
Amount of goodwill at period end	34,544		36,201
Decrease in goodwill associated with foreign currency translation	1,531
Right-of-use assets					$ 4,027
Lease liabilities					$ 4,263
Net foreign exchange gains (losses)	693	$ (609)
Accumulated foreign currency adjustments included in other comprehensive loss amounted	21,243		12,022
Unrealized loss on marketable securities	$ 556		114
Common Stock Options Unvested Restricted Stock and Unvested Performance Stock Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation	312	779
Diversigen, Inc. [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amount of goodwill at period end				$ 6,317
Goodwill, acquired during period	$ 126
Patent and Product Rights [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Patent and product rights acquisition	$ 2,250
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 21,660		$ 1,624

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
OPERATING ACTIVITIES:
Net loss	$ (7,328)	$ (3,258)
Adjustments to reconcile net loss to net cash provided by operating activities:
Stock-based compensation	1,376	1,231
Depreciation and amortization	2,197	1,726
Provision for doubtful accounts	26	47
Unrealized foreign currency (gain) loss	(224)	231
Interest expense on finance leases	20	4
Deferred income taxes	(71)	(85)
Change in the estimated fair value of acquisition-related contingent consideration	1,110	1,295
Payment of acquisition-related contingent consideration	(496)
Changes in assets and liabilities
Accounts receivable	8,623	10,494
Inventories	248	(2,917)
Prepaid expenses and other assets	1,035	416
Accounts payable	(3,094)	(253)
Deferred revenue	780	661
Accrued expenses and other liabilities	(1,703)	(9,064)
Net cash provided by operating activities	2,499	528
INVESTING ACTIVITIES:
Purchases of investments	(36,945)	(44,954)
Proceeds from maturities and redemptions of investments	55,811	44,624
Purchases of property and equipment	(2,595)	(2,628)
Proceeds from escrow associated with business acquisitions	126
Acquisition of businesses, net of cash acquired		(13,256)
Purchase of patent and product rights	(2,250)
Net cash provided by (used in) investing activities	14,147	(16,214)
FINANCING ACTIVITIES:
Repayments of loans		(724)
Cash payments for lease liabilities	(175)	(35)
Payment of acquisition-related contingent consideration	(3,004)
Proceeds from exercise of stock options	30	22
Repurchase of common stock	(1,408)	(3,595)
Net cash used in financing activities	(4,557)	(4,332)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(4,439)	1,096
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	7,650	(18,922)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	75,715	88,438
CASH AND CASH EQUIVALENTS, END OF PERIOD	83,365	69,516
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid (received) for income taxes	(85)	4,397
Non-cash investing and financing activities
Accrued property and equipment purchases	1,129	563
Unrealized gain (loss) on marketable securities	$ (442)	$ 497

Revenues

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Revenues

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended March 31,
	2020		2019
OraQuick®	$	13,756	$	11,590
Oragene®		9,633		4,173
ORAcollect®		449		3,225
Intercept®		1,978		1,842
Microbiome laboratory services		2,447		958
OMNIgene® • GUT		693		979
Histofreezer®⁽¹⁾		-		2,213
Other products		1,930		3,352
Net product and services revenues		30,886		28,332

Royalty income		446		1,084
Other non product revenues		264		706
Other revenues		710		1,790
Net revenues	$	31,596	$	30,122

⁽¹⁾

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended March 31,
	2020		2019
United States	$	21,616	$	20,566
Europe		2,805		2,431
Other regions		7,175		7,125
	$	31,596	$	30,122

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Nov. 08, 2019	Jan. 04, 2019
Assets Acquired
Goodwill	$ 34,544	$ 36,201
Corebiome Inc. and Novosanis NV [Member]
Assets Acquired
Accounts receivable				$ 791
Inventories				310
Other current assets				82
Property, plant, and equipment, net				414
Other assets				5
Acquired intangible assets				8,400
Goodwill				10,368
Total assets acquired				20,370
Liabilities Assumed
Current liabilities				1,180
Notes payable, short-term				730
Deferred tax liability				819
Other long-term liabilities				74
Total liabilities assumed				2,803
Net Assets Acquired				17,567
Estimated fair value of contingent consideration		$ (3,612)		(4,350)
Net Cash Paid				$ 13,217
Diversigen, Inc. [Member]
Assets Acquired
Accounts receivable			$ 1,234
Other current assets			45
Property, plant, and equipment, net			1,916
Acquired intangible assets			3,560
Goodwill			6,317
Total assets acquired			13,072
Liabilities Assumed
Current liabilities			1,123
Deferred tax liability			598
Other long-term liabilities			893
Total liabilities assumed			2,614
Net Cash Paid			$ 10,458

Leases

3 Months Ended

Mar. 31, 2020

Lessee Disclosure [Abstract]

Leases

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of March 31, 2020, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:

	Three Months Ended March 31,
	2020		2019
Operating Lease Cost	$	313	$	231
Finance Lease Cost
Amortization of right-of use assets		163		39
Interest on lease liabilities		20		4
Total Finance Lease Cost	$	183	$	43

Supplemental cash flow information related to leases is as follows:

	Three Months Ended March 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	316	$	228
Operating cash flows from financing leases		20		3
Financing cash flows from financing leases		175		35
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		—		240
Right-of-use assets obtained in exchange for finance lease obligations		—		1,249

Supplemental balance sheet information related to leases is as follows:

	March 31, 2020		December 31, 2019
Operating Leases
Right-of-use assets	$	4,665	$	4,996

Current lease liabilities		999		1,032
Non-current lease liabilities		3,899		4,206
Total operating lease liabilities	$	4,898	$	5,238


Finance Leases
Right-of-use assets	$	1,818	$	1,951

Current lease liabilities		588		613
Non-current lease liabilities		1,281		1,372
Total finance lease liabilities	$	1,869	$	1,985

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.05
Weighted-average remaining lease term—finance leases	3.27

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.29	%
Weighted-average discount rate—finance leases	4.32	%

As of March 31, 2020, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2020 (excluding the three months ended March 31, 2020)	$	512		$	928
2021		565			1,180
2022		565			1,161
2023		336			758
2024		24			776
Thereafter		4			760
Total Minimum Lease Payments		2,006			5,563
Less: imputed interest		(137	)		(665	)
Present Value of Lease Liabilities	$	1,869		$	4,898

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2020 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	525
Shares, Granted	353
Performance adjustment	103
Shares, Vested	(311)
Shares, Forfeited	(35)
Shares, Issued and unvested, Ending Balance	635

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 712,000	$ (29,000)
U.S. federal or state deferred income tax expense or benefits	$ 0

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2020 shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options, Outstanding, Beginning Balance	1,193
Options, Granted	510
Options, Exercised	(6)
Options, Forfeited	(14)
Options, Outstanding, Ending Balance	1,683

Stockholders' Equity - Summary of Time-Vested Restricted Stock Award and Restricted Stock Units Activity (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2020 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	464
Shares, Granted	480
Shares, Vested	(178)
Shares, Forfeited	(10)
Shares, Issued and unvested, Ending Balance	756

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands			3 Months Ended
	Nov. 08, 2019	Jan. 04, 2019	Mar. 31, 2019
Business Acquisition [Line Items]
Net of cash acquired			$ 13,256
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Net of cash acquired		$ 103
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Net of cash acquired	$ 479

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
NET LOSS	$ (7,328)	$ (3,258)
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	(9,221)	2,232
Unrealized gain (loss) on marketable securities	(442)	497
COMPREHENSIVE LOSS	$ (16,991)	$ (529)

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Lease Cost [Abstract]
Operating Lease Cost	$ 313	$ 231
Finance Lease Cost
Amortization of right-of use assets	163	39
Interest on lease liabilities	20	4
Total Finance Lease Cost	$ 183	$ 43

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating Leases
Right-of-use assets	$ 4,665	$ 4,996
Current lease liabilities	999	1,032
Non-current lease liabilities	3,899	4,206
Total operating lease liabilities	4,898	5,238
Finance Leases
Right-of-use assets	1,818	1,951
Current lease liabilities	588	613
Non-current lease liabilities	1,281	1,372
Total finance lease liabilities	$ 1,869	$ 1,985

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 2,511	$ 2,666
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	62,026,000	61,731,000
Common stock, shares outstanding	62,026,000	61,731,000

Leases - Additional Information (Detail)	3 Months Ended
Leases - Additional Information (Detail)	Mar. 31, 2020
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	7 years

The Company - Additional Information (Detail)	3 Months Ended
The Company - Additional Information (Detail)	Mar. 31, 2020 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Detail) - CoreBiome Inc. Diversign and Novosanis NV [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019 USD ($) $ / shares
Business Acquisition [Line Items]
Revenue	$ 31,048
Net loss	$ (3,290)
Net loss per share, basic and diluted \| $ / shares	$ (0.05)

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 93,361	$ 114,157
Gross Unrealized Gains	94	271
Gross Unrealized Losses	(650)	(385)
Fair Value	92,805	114,043
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	22,757	24,632
Gross Unrealized Gains	0	0
Fair Value	22,757	24,632
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	70,604	89,525
Gross Unrealized Gains	94	271
Gross Unrealized Losses	(650)	(385)
Fair Value	70,048	$ 89,411
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	83,274
Gross Unrealized Gains	94
Gross Unrealized Losses	(633)
Fair Value	82,735
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	10,087
Gross Unrealized Gains	0
Gross Unrealized Losses	(17)
Fair Value	$ 10,070

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Net [Abstract]
Raw materials	$ 13,927	$ 14,168
Work in process	865	643
Finished goods	7,902	8,344
Inventories	$ 22,694	$ 23,155

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,376,000	$ 1,231,000
Proceeds from exercise of stock options	30,000	22,000
Income tax benefit realized from stock option exercises during period	0	0
Amount share repurchase program of common shares			$ 25,000,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	253,000	324,000
Proceeds from exercise of stock options	30,000	22,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,079,000	$ 653,000
Vesting of restricted shares, withholding and exercise obligations	197,000	277,000
Restricted shares of common stock, aggregate values	$ 1,408,000	$ 3,595,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 44,000	$ 254,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 316	$ 228
Operating cash flows from financing leases	20	3
Financing cash flows from financing leases	$ 175	35
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		240
Right-of-use assets obtained in exchange for finance lease obligations		$ 1,249

Business Combinations - Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives (Detail) - USD ($) $ in Thousands	Nov. 08, 2019	Jan. 04, 2019
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 8,400
Corebiome Inc. and Novosanis NV [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 5,000
Acquired intangibles, Estimated Useful Life		10 years
Corebiome Inc. and Novosanis NV [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 2,200
Acquired intangibles, Estimated Useful Life		10 years
Corebiome Inc. and Novosanis NV [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 1,200
Acquired intangibles, Estimated Useful Life		8 years 4 months 2 days
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 3,560
Diversigen, Inc. [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 2,900
Acquired intangibles, Estimated Useful Life	10 years
Diversigen, Inc. [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 660
Acquired intangibles, Estimated Useful Life	9 years

Leases - Summary of Lease Term and Discount Rate (Detail)	Mar. 31, 2020
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5 years 18 days
Weighted-average remaining lease term—finance leases	3 years 3 months 7 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.29%
Weighted-average discount rate—finance leases	4.32%

Revenues - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
Revenues - Additional Information (Detail) $ in Thousands	Mar. 31, 2020 USD ($) Supplier	Mar. 31, 2019	Dec. 31, 2019 USD ($)
Revenue from contract with customer [Line Items]
Deferred revenue	$ 4,312		$ 3,713
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	1,804		1,809
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	$ 2,508		$ 1,904
DNA Genotek [Member]
Revenue from contract with customer [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier	2
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	12.00%		19.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member] \| Maximum [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	10.00%	10.00%

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 5,414	$ 6,088
Professional fees	2,364	2,769
Other	4,561	5,431
Accrued expenses and other current liabilities, Total	$ 12,339	$ 14,288

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finance Lease Liabilities, Payments, Due [Abstract]
2020 (excluding the three months ended March 31, 2020)	$ 512
2021	565
2022	565
2023	336
2024	24
Thereafter	4
Total Minimum Finance Lease Payments	2,006
Less: imputed interest	(137)
Present Value of Finance Lease Liabilities	1,869	$ 1,985
Operating Lease Liabilities, Payments Due [Abstract]
2020 (excluding the three months ended March 31, 2020)	928
2021	1,180
2022	1,161
2023	758
2024	776
Thereafter	760
Total Minimum Operating Lease Payments	5,563
Less: imputed interest	(665)
Present Value of Operating Lease Liabilities	$ 4,898	$ 5,238